Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

TNF Inhibitors Do Not Seem to Boost Cancer-Recurrence Rates

Will Boggs, MD  |  August 15, 2018

NEW YORK (Reuters Health)—Tumor necrosis factor (TNF) inhibitors do not appear to increase cancer-recurrence rates in patients with rheumatoid arthritis (RA), according to new findings from Sweden.

TNF has both tumor-promoting and cancer-protective effects, so TNF inhibitors could conceivably affect the risk for cancer recurrence. However, few studies have reported the risk for cancer relapse or second primary tumors in patients with RA who received TNF inhibitor treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pauline Raaschou, MD, PhD, from Karolinska Institutet, Stockholm, and colleagues used data from linked Swedish registries to compare cancer recurrences in RA patients who had started TNF inhibitor treatment after their cancer diagnosis vs. those who remained biologics-naive.

The first, most inclusive comparison matched 467 patients who started TNF inhibitor treatment between 2001 and 2015 after a cancer diagnosis an average of eight years earlier and 2,164 biologics-naive patients with a history of cancer. During a mean 5.3 years of follow-up in the TNF inhibitor group and 4.3 years in the comparison group, recurrence rates did not differ significantly between the groups (9.0% vs. 7.2%, respectively).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

After restricting the groups to patients whose cancer was diagnosed in 2001 or later, there was still no significant difference in recurrence rates (10% of those treated with TNF inhibitors vs. 7.3%), the researchers report in the Aug. 14 issue of Annals of Internal Medicine.1

In the most restrictive matched analysis (patients whose index cancer occurred in 2003 or later), the risk of cancer recurrence remained similar in patients treated with and without TNF inhibitors.

Finally, cancer recurrence rates did not differ significantly between the groups in an unmatched analysis.

“Our findings suggest that TNF inhibitor treatment was not associated with an increased risk for cancer recurrence in patients with RA and a history of cancer compared with those who had a similar cancer history and were selected to receive other RA treatments,” the researchers conclude. “However, as suggested by the upper limit of the confidence interval for several risk estimates, a clinically meaningful risk cannot be completely ruled out.”

They add, “Our results should be interpreted in light of the treatment channeling that is part of clinical practice and may not be directly applicable to patients with ongoing cancer or a recent cancer diagnosis or to all cancer types.”

Dr. Kimme Hyrich from The University of Manchester’s Arthritis Research U.K. Center for Epidemiology, in the U.K., who earlier reported that TNF inhibitors did not appear to increase cancer-recurrence rates in U.K. RA patients, tells Reuters Health by email the new results “add to the reassuring data that a past history of cancer is not an absolute contraindication for future TNF inhibitor therapies.”

“However,” she says, “whether or not to start a TNF inhibitor in this situation should remain an individual shared decision between physician and patient.”

“A majority of cancers observed in this study were Stage 1 or 2, and the study did not include all cancer types, so the results of this analysis may not apply to all patients,” Dr. Hyrich says. “It also does not tell us the best approach for patients with no history of cancer who develop a cancer for the first time while receiving a TNF inhibitor.”

Dr. Raaschou did not respond to a request for comments.


Reference

  1. Raaschou P, Söderling J, Turesson C, et al. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: A nationwide population-based cohort study. Ann Intern Med. 2018 Aug 14. doi: 10.7326/M17-2812. [Epub ahead of print]

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:CancerRheumatoid Arthritis (RA)TNF inhibitors

Related Articles

    Are We Playing It Safe?

    October 1, 2010

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies

    Reading Rheum

    August 1, 2009

    Handpicked Reviews of Contemporary Literature

    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences